DIAMEDICA THERAPEUTICS INC (DMAC) Stock News

USA - NASDAQ:DMAC - CA25253X2077 - Common Stock

5.92 USD

-0.3 (-4.82%)

Last: 11/7/2025, 8:00:01 PM

6.03 USD

+0.11 (+1.86%)

After Hours: 11/7/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

DMAC Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025

26 days ago - By: Benzinga - Mentions: LIXT SSKN ENTX GNPX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

a month ago - By: DiaMedica Therapeutics Inc.

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

2 months ago - By: Zacks Investment Research

DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

3 months ago - By: Benzinga

Exploring DiaMedica Therapeutics's Earnings Expectations

2 months ago - By: Zacks Investment Research

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright

2 months ago - By: Zacks Investment Research

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

2 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

2 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

2 months ago - By: Zacks Investment Research

What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?

3 months ago - By: Zacks Investment Research

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?

3 months ago - By: The Motley Fool

DiaMedica Posts Narrower Loss in Q2

3 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

3 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

3 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

4 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

4 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

4 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

5 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May

6 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025

8 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results

8 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

9 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors

9 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke

9 months ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

a year ago - By: DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia